Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on RARE stock, giving a Buy rating on July 28.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Schwartz has given his Buy rating due to a combination of factors surrounding Ultragenyx Pharmaceutical’s recent developments. The company has achieved full enrollment in the pivotal Aspire study for apazunersen, which is a promising sign for its potential success in treating Angelman syndrome. This rapid enrollment highlights the significant unmet need for treatment in this area and suggests a strong commercial opportunity.
Additionally, despite recent setbacks with other programs, such as the ORBIT study with setrusumab and the UX111 program, the progress in the Aspire study is encouraging. The study’s design, which includes a robust primary endpoint and a high probability of detecting a treatment effect, further supports the potential for positive outcomes. With the anticipated completion of the Aspire study in the second half of 2026 and a possible US launch in 2027, Schwartz sees a favorable outlook for Ultragenyx’s stock, reinforcing his Buy recommendation.
In another report released on July 28, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $80.00 price target.
Based on the recent corporate insider activity of 45 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RARE in relation to earlier this year.